Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1272

1.

Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Hari P, Paba-Prada CE, Voorhees PM, Frye J, Chang YL, Moreau P, Zonder J, Boccia R, Shain KH.

Leuk Res. 2019 Jun 17;83:106172. doi: 10.1016/j.leukres.2019.106172. [Epub ahead of print]

PMID:
31229804
2.

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.

Boyle EM, Leleu X, Petillon MO, Karlin L, Doyen C, Demarquette H, Royer B, Macro M, Moreau P, Fostier K, Marie-Lorraine C, Zarnitsky C, Perrot A, Herbaux C, Poulain S, Manier S, Beauvais D, Walker BA, Wardell CP, Vincent L, Frenzel L, Caillon H, Susanna S, Dejoie T, Avet-Loiseau H, Mohty M, Facon T; IFM2014-04 investigators.

Br J Haematol. 2019 Jun 19. doi: 10.1111/bjh.16059. [Epub ahead of print]

PMID:
31218679
3.

[Alcohol consumption and head and neck cancer].

Goffinet M, Ransy P, Bouchain O, Lefebvre P, Moreau P.

Rev Med Liege. 2019 May;74(5-6):349-353. French.

4.

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma.

Adamia S, Abiatari I, Amin SB, Fulciniti M, Minvielle S, Li C, Moreau P, Avet-Loiseau H, Munshi NC, Anderson KC.

Leukemia. 2019 Jun 10. doi: 10.1038/s41375-019-0498-5. [Epub ahead of print]

PMID:
31182781
5.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P.

Lancet. 2019 Jun 3. pii: S0140-6736(19)31240-1. doi: 10.1016/S0140-6736(19)31240-1. [Epub ahead of print] Erratum in: Lancet. 2019 Jun 14;:.

PMID:
31171419
6.

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.

Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M.

Clin Lymphoma Myeloma Leuk. 2019 May 2. pii: S2152-2650(19)30028-X. doi: 10.1016/j.clml.2019.04.018. [Epub ahead of print]

PMID:
31160237
7.

Correction of adult spinal deformity with a minimally invasive fusionless bipolar construct: Preliminary results.

Wolff S, Habboubi K, Sebaaly A, Moreau PE, Miladi L, Riouallon G.

Orthop Traumatol Surg Res. 2019 May 29. pii: S1877-0568(19)30091-X. doi: 10.1016/j.otsr.2019.02.015. [Epub ahead of print] Review.

PMID:
31153861
8.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators.

N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.

PMID:
31141632
9.

Early warning sensors for monitoring mercury in water.

Pinaeva U, Lairez D, Oral O, Faber A, Clochard MC, Wade TL, Moreau P, Ghestem JP, Vivier M, Ammor S, Nocua R, Soulé A.

J Hazard Mater. 2019 Aug 15;376:37-47. doi: 10.1016/j.jhazmat.2019.05.023. Epub 2019 May 14.

PMID:
31121451
10.

Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P.

Blood. 2019 May 21. pii: blood.2019000722. doi: 10.1182/blood.2019000722. [Epub ahead of print]

PMID:
31113777
11.

Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study).

Moreau P, Kumar S, Boccia R, Iida S, Goldschmidt H, Cocks K, Trigg A, Zahlten-Kumeli A, Yucel E, Panjabi SS, Dimopoulos M.

Leukemia. 2019 May 15. doi: 10.1038/s41375-019-0480-2. [Epub ahead of print]

PMID:
31092895
12.

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.

Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Fontan J, Voillat L, Demarquette H, Collet P, Rodon P, Sohn C, Lifermann F, Orsini-Piocelle F, Richez V, Mohty M, Macro M, Minvielle S, Moreau P, Leleu X, Facon T, Attal M, Avet-Loiseau H, Corre J.

J Clin Oncol. 2019 May 15:JCO1800776. doi: 10.1200/JCO.18.00776. [Epub ahead of print]

PMID:
31091136
13.

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.

Mateos MV, Orlowski RZ, Ocio EM, Rodríguez-Otero P, Reece D, Moreau P, Munshi N, Avigan DE, Siegel DS, Ghori R, Farooqui MZH, Marinello P, San-Miguel J.

Br J Haematol. 2019 May 15. doi: 10.1111/bjh.15946. [Epub ahead of print] No abstract available.

PMID:
31090915
14.

Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.

Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C, Chevallier P, Vigouroux S, Peterlin P, Garnier A, Rubio MT, Huynh A, Milpied N, Moreau P, Gaugler B, Yakoub-Agha I, Mohty M.

Bone Marrow Transplant. 2019 May 14. doi: 10.1038/s41409-019-0536-y. [Epub ahead of print]

PMID:
31089280
15.

HLA-G expression during hookworm infection in pregnant women.

Avokpaho E, d'Almeida TC, Sadissou I, Tokplonou L, Adamou R, Sonon P, Milet J, Cottrell G, Mondière A, Massougbodji A, Moutairou K, Donadi EA, Teixeira Mendes Junior C, Favier B, Carosella E, Moreau P, Rouas-Freiss N, Garcia A, Courtin D.

Acta Trop. 2019 May 9;196:52-59. doi: 10.1016/j.actatropica.2019.04.026. [Epub ahead of print]

PMID:
31078470
16.

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Leleu X, Fouquet G, Richez V, Guidez S, Duhamel A, Machuron F, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Roussel M, Jaccard A, Pétillon MO, Belhadj-Merzoug K, Lepeu G, Chrétien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Attal M, Moreau P, Avet-Loiseau H, Hulin C, Facon T.

Clin Cancer Res. 2019 May 3. doi: 10.1158/1078-0432.CCR-18-3642. [Epub ahead of print]

PMID:
31053600
17.

Theoretical assessment of the OTDR detector noise on plasma current measurement in tokamaks.

Motuz R, Leysen W, Moreau P, Gusarov A, Drexler P, Wuilpart M.

Appl Opt. 2019 Apr 10;58(11):2795-2802. doi: 10.1364/AO.58.002795.

PMID:
31044879
18.

FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Cytokine. 2019 Aug;120:85-87. doi: 10.1016/j.cyto.2019.04.015. Epub 2019 Apr 28.

PMID:
31035172
19.

Interest of Pet Imaging in Multiple Myeloma.

Jamet B, Bailly C, Carlier T, Touzeau C, Nanni C, Zamagni E, Barré L, Michaud AV, Chérel M, Moreau P, Bodet-Milin C, Kraeber-Bodéré F.

Front Med (Lausanne). 2019 Apr 9;6:69. doi: 10.3389/fmed.2019.00069. eCollection 2019. Review.

20.

New insights in the treatment of patients with solitary bone plasmacytoma.

Mheidly K, Lamy De La Chapelle T, Hunault M, Benboubker L, Benchalal M, Moreau P, Baugier de Materre A, Decaux O, Laribi K.

Leuk Lymphoma. 2019 Apr 25:1-4. doi: 10.1080/10428194.2019.1605067. [Epub ahead of print] No abstract available.

PMID:
31020888
21.

Thermomechanical Polymer Binder Reactivity with Positive Active Materials for Li Metal Polymer and Li-Ion Batteries: An XPS and XPS Imaging Study.

Grissa R, Abramova A, Tambio SJ, Lecuyer M, Deschamps M, Fernandez V, Greneche JM, Guyomard D, Lestriez B, Moreau P.

ACS Appl Mater Interfaces. 2019 May 22;11(20):18368-18376. doi: 10.1021/acsami.9b01761. Epub 2019 May 8.

PMID:
31020833
22.

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Pertesi M, Vallée M, Wei X, Revuelta MV, Galia P, Demangel D, Oliver J, Foll M, Chen S, Perrial E, Garderet L, Corre J, Leleu X, Boyle EM, Decaux O, Rodon P, Kolb B, Slama B, Mineur P, Voog E, Le Bris C, Fontan J, Maigre M, Beaumont M, Azais I, Sobol H, Vignon M, Royer B, Perrot A, Fuzibet JG, Dorvaux V, Anglaret B, Cony-Makhoul P, Berthou C, Desquesnes F, Pegourie B, Leyvraz S, Mosser L, Frenkiel N, Augeul-Meunier K, Leduc I, Leyronnas C, Voillat L, Casassus P, Mathiot C, Cheron N, Paubelle E, Moreau P, Bignon YJ, Joly B, Bourquard P, Caillot D, Naman H, Rigaudeau S, Marit G, Macro M, Lambrecht I, Cliquennois M, Vincent L, Helias P, Avet-Loiseau H, Moreno V, Reis RM, Varkonyi J, Kruszewski M, Vangsted AJ, Jurczyszyn A, Zaucha JM, Sainz J, Krawczyk-Kulis M, Wątek M, Pelosini M, Iskierka-Jażdżewska E, Grząśko N, Martinez-Lopez J, Jerez A, Campa D, Buda G, Lesueur F, Dudziński M, García-Sanz R, Nagler A, Rymko M, Jamroziak K, Butrym A, Canzian F, Obazee O, Nilsson B, Klein RJ, Lipkin SM, McKay JD, Dumontet C.

Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0452-6. [Epub ahead of print] No abstract available.

PMID:
30967618
23.

Kinase inhibitions in pyrido[4,3-h] and [3,4-g]quinazolines: Synthesis, SAR and molecular modeling studies.

Zeinyeh W, Esvan YJ, Josselin B, Baratte B, Bach S, Nauton L, Théry V, Ruchaud S, Anizon F, Giraud F, Moreau P.

Bioorg Med Chem. 2019 May 15;27(10):2083-2089. doi: 10.1016/j.bmc.2019.04.005. Epub 2019 Apr 4.

PMID:
30967303
24.

Developmental control of plant Rho GTPase nano-organization by the lipid phosphatidylserine.

Platre MP, Bayle V, Armengot L, Bareille J, Marquès-Bueno MDM, Creff A, Maneta-Peyret L, Fiche JB, Nollmann M, Miège C, Moreau P, Martinière A, Jaillais Y.

Science. 2019 Apr 5;364(6435):57-62. doi: 10.1126/science.aav9959.

PMID:
30948546
25.

The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis?

Dargaud Y, Fouassier M, Bordet JC, Ducastelle-Lepretre S, Dumontet C, Moreau P, Michallet M.

Leuk Lymphoma. 2019 Apr 3:1-4. doi: 10.1080/10428194.2019.1585839. [Epub ahead of print] No abstract available.

PMID:
30942646
26.

CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.

Papin A, Tessoulin B, Bellanger C, Moreau A, Le Bris Y, Maisonneuve H, Moreau P, Touzeau C, Amiot M, Pellat-Deceunynck C, Le Gouill S, Chiron D.

Leukemia. 2019 Apr 2. doi: 10.1038/s41375-019-0463-3. [Epub ahead of print]

PMID:
30940906
27.

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

Plesner T, Arkenau HT, Gay F, Minnema MC, Boccadoro M, Moreau P, Cavenagh J, Perrot A, Laubach JP, Krejcik J, Ahmadi T, de Boer C, Chen D, Chiu C, Schecter JM, Richardson PG.

Br J Haematol. 2019 Mar 31. doi: 10.1111/bjh.15879. [Epub ahead of print] No abstract available.

PMID:
30931524
28.

Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies.

Bouard L, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Duquenne A, Mahe B, Dubruille V, Blin N, Touzeau C, Gastinne T, Le Bris Y, Lok A, Bonnet A, Le Gouill S, Moreau P, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2019 Mar 27. pii: S1083-8791(19)30209-5. doi: 10.1016/j.bbmt.2019.03.025. [Epub ahead of print]

PMID:
30928627
29.

Deciphering the chronology of copy number alterations in Multiple Myeloma.

Aktas Samur A, Minvielle S, Shammas M, Fulciniti M, Magrangeas F, Richardson PG, Moreau P, Attal M, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK.

Blood Cancer J. 2019 Mar 26;9(4):39. doi: 10.1038/s41408-019-0199-3.

30.

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide.

Moreau P, Zamagni E, Mateos MV.

Blood Cancer J. 2019 Mar 20;9(4):38. doi: 10.1038/s41408-019-0200-1.

31.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.

Trudel S, Tessoulin B, Jullien M, Blin N, Gastinne T, Mahé B, Dubruille V, Bonnet A, Lok A, Chevallier P, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Le Gouill S, Moreau P, Touzeau C.

Ann Hematol. 2019 Jun;98(6):1441-1447. doi: 10.1007/s00277-019-03649-3. Epub 2019 Mar 14.

PMID:
30874851
32.

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.

Jullien M, Trudel S, Tessoulin B, Mahé B, Dubruille V, Blin N, Gastinne T, Bonnet A, Lok A, Lebourgeois A, Peterlin P, Garnier A, Chevalier P, Guillaume T, Thomaré P, Le Gouill S, Moreau P, Touzeau C.

Ann Hematol. 2019 Jun;98(6):1435-1440. doi: 10.1007/s00277-019-03655-5. Epub 2019 Mar 14.

PMID:
30874850
33.

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J.

Blood. 2019 May 2;133(18):1953-1963. doi: 10.1182/blood-2018-09-874396. Epub 2019 Feb 28.

PMID:
30819926
34.

Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.

Caillon H, Avet-Loiseau H, Attal M, Moreau P, Decaux O, Dejoie T.

Clin Lymphoma Myeloma Leuk. 2019 May;19(5):e228-e237. doi: 10.1016/j.clml.2019.01.007. Epub 2019 Jan 29.

PMID:
30799237
35.

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.

Ludwig H, Moreau P, Dimopoulos MA, Mateos MV, Kaiser M, Hajek R, Feng S, Cocks K, Buchanan J, Weisel K.

Blood Cancer J. 2019 Feb 22;9(3):23. doi: 10.1038/s41408-019-0181-0.

36.

18F-FDG PET/CT in multiple myeloma: critical insights and future directions.

Bailly C, Carlier T, Jamet B, Touzeau C, Moreau P, Kraeber-Bodéré F, Bodet-Milin C.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1048-1050. doi: 10.1007/s00259-019-04279-7. Epub 2019 Feb 15. No abstract available.

PMID:
30770949
37.

New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.

Tazarki H, Zeinyeh W, Esvan YJ, Knapp S, Chatterjee D, Schröder M, Joerger AC, Khiari J, Josselin B, Baratte B, Bach S, Ruchaud S, Anizon F, Giraud F, Moreau P.

Eur J Med Chem. 2019 Mar 15;166:304-317. doi: 10.1016/j.ejmech.2019.01.052. Epub 2019 Jan 26.

PMID:
30731399
38.

Hidden fungal diversity from the Neotropics: Geastrum hirsutum, G. schweinitzii (Basidiomycota, Geastrales) and their allies.

Accioly T, Sousa JO, Moreau PA, Lécuru C, Silva BDB, Roy M, Gardes M, Baseia IG, Martín MP.

PLoS One. 2019 Feb 6;14(2):e0211388. doi: 10.1371/journal.pone.0211388. eCollection 2019.

39.

[Update of the recommendations of good clinical practice for the use of PET in oncology].

Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, Coriat R, Hindie E, Taieb D, Tabarin A, Girard A, Grellier JF, Brenot-Rossi I, Groheux D, Rousseau C, Deandreis D, Alberini JL, Bodet-Milin C, Itti E, Casasnovas O, Kraeber-Bodere F, Moreau P, Philip A, Balleyguier C, Lucian A, Cachin F.

Bull Cancer. 2019 Mar;106(3):262-274. doi: 10.1016/j.bulcan.2019.01.002. Epub 2019 Jan 23. French.

PMID:
30683308
40.

A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia.

Bjørnstad R, Aesoy R, Bruserud Ø, Brenner AK, Giraud F, Dowling TH, Gausdal G, Moreau P, Døskeland SO, Anizon F, Herfindal L.

Mol Cancer Ther. 2019 Mar;18(3):567-578. doi: 10.1158/1535-7163.MCT-17-1234. Epub 2019 Jan 24.

PMID:
30679386
41.

FLT3 ligand plasma levels in acute myeloid leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Haematologica. 2019 Jun;104(6):e240-e243. doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10. No abstract available.

42.

Diversity of Chroogomphus (Gomphidiaceae, Boletales) in Europe, and typification of C. rutilus.

Scambler R, Niskanen T, Assyov B, Ainsworth AM, Bellanger JM, Loizides M, Moreau PA, Kirk PM, Liimatainen K.

IMA Fungus. 2018 Jul;9:271-290. doi: 10.5598/imafungus.2018.09.02.04. Epub 2018 Sep 5.

43.

Posterior dislocation of the long head biceps tendon: a case report, specific radiographic finding, and review of the literature.

Moreau P, Bresler M, Goldberg B, Mar WA.

Skeletal Radiol. 2019 Jul;48(7):1131-1135. doi: 10.1007/s00256-018-3137-8. Epub 2019 Jan 5. Review.

PMID:
30612160
44.

Acto-myosin force organization modulates centriole separation and PLK4 recruitment to ensure centriole fidelity.

Vitiello E, Moreau P, Nunes V, Mettouchi A, Maiato H, Ferreira JG, Wang I, Balland M.

Nat Commun. 2019 Jan 3;10(1):52. doi: 10.1038/s41467-018-07965-6.

45.

Percutaneous fixation of thoracolumbar vertebral fractures.

Sebaaly A, Rizkallah M, Riouallon G, Wang Z, Moreau PE, Bachour F, Maalouf G.

EFORT Open Rev. 2018 Nov 19;3(11):604-613. doi: 10.1302/2058-5241.3.170026. eCollection 2018 Nov.

46.

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements.

Dejoie T, Corre J, Caillon H, Moreau P, Attal M, Loiseau HA.

Leukemia. 2019 Feb;33(2):313-318. doi: 10.1038/s41375-018-0339-y. Epub 2018 Dec 20. Review.

47.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.

PMID:
30545780
48.

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.

Tessoulin B, Moreau-Aubry A, Descamps G, Gomez-Bougie P, Maïga S, Gaignard A, Chiron D, Ménoret E, Le Gouill S, Moreau P, Amiot M, Pellat-Deceunynck C.

J Hematol Oncol. 2018 Dec 13;11(1):137. doi: 10.1186/s13045-018-0679-0.

49.

p53 regulates CD46 expression and measles virus infection in myeloma cells.

Lok A, Descamps G, Tessoulin B, Chiron D, Eveillard M, Godon C, Le Bris Y, Vabret A, Bellanger C, Maillet L, Barillé-Nion S, Gregoire M, Fonteneau JF, Le Gouill S, Moreau P, Tangy F, Amiot M, Moreau-Aubry A, Pellat-Deceunynck C.

Blood Adv. 2018 Dec 11;2(23):3492-3505. doi: 10.1182/bloodadvances.2018025106.

50.

Fungal Planet description sheets: 716-784.

Crous PW, Wingfield MJ, Burgess TI, Hardy GESJ, Gené J, Guarro J, Baseia IG, García D, Gusmão LFP, Souza-Motta CM, Thangavel R, Adamčík S, Barili A, Barnes CW, Bezerra JDP, Bordallo JJ, Cano-Lira JF, de Oliveira RJV, Ercole E, Hubka V, Iturrieta-González I, Kubátová A, Martín MP, Moreau PA, Morte A, Ordoñez ME, Rodríguez A, Stchigel AM, Vizzini A, Abdollahzadeh J, Abreu VP, Adamčíková K, Albuquerque GMR, Alexandrova AV, Álvarez Duarte E, Armstrong-Cho C, Banniza S, Barbosa RN, Bellanger JM, Bezerra JL, Cabral TS, Caboň M, Caicedo E, Cantillo T, Carnegie AJ, Carmo LT, Castañeda-Ruiz RF, Clement CR, Čmoková A, Conceição LB, Cruz RHSF, Damm U, da Silva BDB, da Silva GA, da Silva RMF, de A Santiago ALCM, de Oliveira LF, de Souza CAF, Déniel F, Dima B, Dong G, Edwards J, Félix CR, Fournier J, Gibertoni TB, Hosaka K, Iturriaga T, Jadan M, Jany JL, Jurjević Ž, Kolařík M, Kušan I, Landell MF, Leite Cordeiro TR, Lima DX, Loizides M, Luo S, Machado AR, Madrid H, Magalhães OMC, Marinho P, Matočec N, Mešić A, Miller AN, Morozova OV, Neves RP, Nonaka K, Nováková A, Oberlies NH, Oliveira-Filho JRC, Oliveira TGL, Papp V, Pereira OL, Perrone G, Peterson SW, Pham THG, Raja HA, Raudabaugh DB, Řehulka J, Rodríguez-Andrade E, Saba M, Schauflerová A, Shivas RG, Simonini G, Siqueira JPZ, Sousa JO, Stajsic V, Svetasheva T, Tan YP, Tkalčec Z, Ullah S, Valente P, Valenzuela-Lopez N, Abrinbana M, Viana Marques DA, Wong PTW, Xavier de Lima V, Groenewald JZ.

Persoonia. 2018 Dec;40:240-393. doi: 10.3767/persoonia.2018.40.10. Epub 2018 Jul 13.

Supplemental Content

Loading ...
Support Center